{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:01:16Z","timestamp":1793257276048,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57147166"],"award-info":[{"award-number":["57147166"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We have queried the Surveillance, Epidemiology and End-Results \u201cSEER\u201d-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69\u00a0years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity\/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin\u2019s lymphoma and melanoma as first primary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-020-04896-1","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T06:02:41Z","timestamp":1598940161000},"page":"515-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body"],"prefix":"10.1007","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-4583","authenticated-orcid":false,"given":"Ahmad Samir","family":"Alfaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-0131","authenticated-orcid":false,"given":"Anas M.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-5883","authenticated-orcid":false,"given":"Mahmoud Tawfik","family":"KhalafAllah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-0645","authenticated-orcid":false,"given":"Omneya Ezzat","family":"Elsherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-8476","authenticated-orcid":false,"given":"Moataz Hamed","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-8596","authenticated-orcid":false,"given":"Olaf","family":"Strau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"4896_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.canep.2014.07.001","volume":"38","author":"WM Hassan","year":"2014","unstructured":"Hassan WM, Alfaar AS, Bakry MS, Ezzat S (2014) Orbital tumors in USA: difference in survival patterns. Cancer Epidemiol 38:515\u2013522. https:\/\/doi.org\/10.1016\/j.canep.2014.07.001","journal-title":"Cancer Epidemiol"},{"key":"4896_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijrobp.2007.12.043","volume":"72","author":"M Abdel-Wahab","year":"2008","unstructured":"Abdel-Wahab M, Reis IM, Hamilton K (2008) Second primary cancer after radiotherapy for prostate cancer\u2014a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 72:58\u201368. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.12.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4896_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","volume":"93","author":"P Brennan","year":"2005","unstructured":"Brennan P, Sc\u00e9lo G, Hemminki K et al (2005) Second primary cancers among 109 000 cases of non-Hodgkin\u2019s lymphoma. Br J Cancer 93:159\u2013166. https:\/\/doi.org\/10.1038\/sj.bjc.6602654","journal-title":"Br J Cancer"},{"key":"4896_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4048\/jbc.2015.18.4.378","volume":"18","author":"R Marcheselli","year":"2015","unstructured":"Marcheselli R, Marcheselli L, Cortesi L et al (2015) Risk of second primary malignancy in breast cancer survivors: a nested population-based case-control study. J Breast Cancer 18:378\u2013385. https:\/\/doi.org\/10.4048\/jbc.2015.18.4.378","journal-title":"J Breast Cancer"},{"key":"4896_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","volume":"22","author":"M Pirani","year":"2011","unstructured":"Pirani M, Marcheselli R, Marcheselli L et al (2011) Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis. Ann Oncol 22:1845\u20131858. https:\/\/doi.org\/10.1093\/annonc\/mdq697","journal-title":"Ann Oncol"},{"key":"4896_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3892\/or.7.4.761","volume":"7","author":"M Amichetti","year":"2000","unstructured":"Amichetti M, Caffo O, Minatel E et al (2000) Ocular metastases from breast carcinoma: a multicentric retrospective study. Oncol Rep 7:761\u2013765. https:\/\/doi.org\/10.3892\/or.7.4.761","journal-title":"Oncol Rep"},{"key":"4896_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/bjo.81.5.386","volume":"81","author":"DH Char","year":"1997","unstructured":"Char DH, Miller T, Kroll S (1997) Orbital metastases: diagnosis and course. Br J Ophthalmol 81:386\u2013390. https:\/\/doi.org\/10.1136\/bjo.81.5.386","journal-title":"Br J Ophthalmol"},{"key":"4896_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0420.2003.00018.x","volume":"81","author":"P Fahmy","year":"2003","unstructured":"Fahmy P, Heegaard S, Jensen OA, Prause JU (2003) Metastases in the ophthalmic region in Denmark 1969-98. A histopathological study. Acta Ophthalmol Scand 81:47\u201350","journal-title":"Acta Ophthalmol Scand"},{"key":"4896_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1365-4632.2008.03496.x","volume":"47","author":"A Husain","year":"2008","unstructured":"Husain A, Blumenschein G, Esmaeli B (2008) Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol 47:276\u2013279. https:\/\/doi.org\/10.1111\/j.1365-4632.2008.03496.x","journal-title":"Int J Dermatol"},{"key":"4896_CR10","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3980\/j.issn.2222-3959.2015.05.30","volume":"8","author":"P Magliozzi","year":"2015","unstructured":"Magliozzi P, Strianese D, Bonavolont\u00e0 P et al (2015) Orbital metastases in Italy. Int J Ophthalmol 8:1018\u20131023. https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2015.05.30","journal-title":"Int J Ophthalmol"},{"key":"4896_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/01676830902897470","volume":"28","author":"AA Valenzuela","year":"2009","unstructured":"Valenzuela AA, Archibald CW, Fleming B et al (2009) Orbital metastasis: clinical features, management and outcome. Orbit 28:153\u2013159","journal-title":"Orbit"},{"key":"4896_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archophthalmol.2010.126","volume":"128","author":"KI Woo","year":"2010","unstructured":"Woo KI, Harbour JW (2010) Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol 128:865\u2013870. https:\/\/doi.org\/10.1001\/archophthalmol.2010.126","journal-title":"Arch Ophthalmol"},{"key":"4896_CR13","unstructured":"\u2018National Cancer Institute, DCCPS SRP (2017) Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975\u20132016) <Katrina\/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969\u20132017. Accessed 8 July 2020"},{"key":"4896_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1758-3284-3-37","volume":"3","author":"AM Eckardt","year":"2011","unstructured":"Eckardt AM, Rana M, Essig H, Gellrich N-C (2011) Orbital metastases as first sign of metastatic spread in breast cancer: case report and review of the literature. Head Neck Oncol 3:37. https:\/\/doi.org\/10.1186\/1758-3284-3-37","journal-title":"Head Neck Oncol"},{"key":"4896_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3233\/BD-140367","volume":"34","author":"L Rossi","year":"2014","unstructured":"Rossi L, Zancla S, Civitelli L, Ranieri E (2014) An unusual orbital metastasis of breast cancer. Breast Dis 34:173\u2013176. https:\/\/doi.org\/10.3233\/BD-140367","journal-title":"Breast Dis"},{"key":"4896_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2407-11-83","volume":"11","author":"DR Youlden","year":"2011","unstructured":"Youlden DR, Baade PD (2011) The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 11:83. https:\/\/doi.org\/10.1186\/1471-2407-11-83","journal-title":"BMC Cancer"},{"key":"4896_CR17","unstructured":"Curtis R, Freedman D, Ron E et al (2006) New malignancies among cancer survivors: SEER Cancer Registries, 1973\u20132000. Bethesda, MD"},{"key":"4896_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ajo.2016.02.022","volume":"165","author":"I La\u00edns","year":"2016","unstructured":"La\u00edns I, Bartosch C, Mondim V et al (2016) Second primary neoplasms in patients with uveal melanoma: a SEER database analysis. Am J Ophthalmol 165:54\u201364. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.022","journal-title":"Am J Ophthalmol"},{"key":"4896_CR19","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/s0161-6420(01)00713-8","volume":"108","author":"DH Abramson","year":"2001","unstructured":"Abramson DH, Melson MR, Dunkel IJ, Frank CM (2001) Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108:1868\u20131876. https:\/\/doi.org\/10.1016\/s0161-6420(01)00713-8","journal-title":"Ophthalmology"},{"key":"4896_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/archopht.1987.01060090073031","volume":"105","author":"MI Freedman","year":"1987","unstructured":"Freedman MI, Folk JC (1987) Metastatic tumors to the eye and orbit. Patient survival and clinical characteristics. Arch Ophthalmol 105:1215\u20131219. https:\/\/doi.org\/10.1001\/archopht.1987.01060090073031","journal-title":"Arch Ophthalmol"},{"key":"4896_CR21","first-page":"65","volume":"39","author":"I G\u00fcnalp","year":"1995","unstructured":"G\u00fcnalp I, G\u00fcnd\u00fcz K (1995) Metastatic orbital tumors. Jpn J Ophthalmol 39:65\u201370","journal-title":"Jpn J Ophthalmol"},{"key":"4896_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ecc.12109","volume":"23","author":"LG Marcu","year":"2014","unstructured":"Marcu LG, Santos A, Bezak E (2014) Risk of second primary cancer after breast cancer treatment. Eur J Cancer Care (Engl) 23:51\u201364. https:\/\/doi.org\/10.1111\/ecc.12109","journal-title":"Eur J Cancer Care (Engl)"},{"key":"4896_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JGO.2016.003699","volume":"3","author":"BG Silverman","year":"2017","unstructured":"Silverman BG, Lipshitz I, Keinan-Boker L (2017) Second primary cancers after primary breast Cancer diagnosis in Israeli women, 1992 to 2006. J Glob Oncol 3:135\u2013142. https:\/\/doi.org\/10.1200\/JGO.2016.003699","journal-title":"J Glob Oncol"},{"key":"4896_CR24","doi-asserted-by":"publisher","first-page":"e0140693","DOI":"10.1371\/journal.pone.0140693","volume":"10","author":"JY Joung","year":"2015","unstructured":"Joung JY, Lim J, Oh C-M et al (2015) Risk of second primary cancer among prostate cancer patients in Korea: a population-based cohort study. PLoS One 10:e0140693. https:\/\/doi.org\/10.1371\/journal.pone.0140693","journal-title":"PLoS One"},{"key":"4896_CR25","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","volume":"28","author":"LM Morton","year":"2010","unstructured":"Morton LM, Curtis RE, Linet MS et al (2010) Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 28:4935\u20134944. https:\/\/doi.org\/10.1200\/JCO.2010.29.1112","journal-title":"J Clin Oncol"},{"key":"4896_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward JD, Wendland MMM, Shrieve DC et al (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107:108\u2013115. https:\/\/doi.org\/10.1002\/cncr.21971","journal-title":"Cancer"},{"key":"4896_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/0002-9610(72)90079-7","volume":"124","author":"HH Leventhal","year":"1972","unstructured":"Leventhal HH, Messer RJ (1972) Malignant tumors of the eyelid. Am J Surg 124:522\u2013526. https:\/\/doi.org\/10.1016\/0002-9610(72)90079-7","journal-title":"Am J Surg"},{"key":"4896_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2017.02.004","volume":"177","author":"FH Svendsen","year":"2017","unstructured":"Svendsen FH, Rasmussen PK, Coupland SE et al (2017) Lymphoma of the eyelid - an international multicenter retrospective study. Am J Ophthalmol 177:58\u201368. https:\/\/doi.org\/10.1016\/j.ajo.2017.02.004","journal-title":"Am J Ophthalmol"},{"key":"4896_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.survophthal.2016.11.009","volume":"62","author":"FH Svendsen","year":"2017","unstructured":"Svendsen FH, Heegaard S (2017) Lymphoma of the eyelid. Surv Ophthalmol 62:312\u2013331. https:\/\/doi.org\/10.1016\/j.survophthal.2016.11.009","journal-title":"Surv Ophthalmol"},{"key":"4896_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/RLU.0b013e318124fdb6","volume":"32","author":"A Fard-Esfahani","year":"2007","unstructured":"Fard-Esfahani A, Mirshekarpour H, Fallahi B et al (2007) The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 32:696\u2013699. https:\/\/doi.org\/10.1097\/RLU.0b013e318124fdb6","journal-title":"Clin Nucl Med"},{"key":"4896_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bjo.2005.072892","volume":"89","author":"I Rahman","year":"2005","unstructured":"Rahman I, Maino A, Cook AE, Leatherbarrow B (2005) Mortality following exenteration for malignant tumours of the orbit. Br J Ophthalmol 89:1445\u20131448. https:\/\/doi.org\/10.1136\/bjo.2005.072892","journal-title":"Br J Ophthalmol"},{"key":"4896_CR32","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.18240\/ijo.2016.12.18","volume":"9","author":"WM Hassan","year":"2016","unstructured":"Hassan WM, Bakry MS, Hassan HM, Alfaar AS (2016) Incidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from Surveillance, Epidemiology and End Results, 1973-2009. Int J Ophthalmol 9:1808\u20131813. https:\/\/doi.org\/10.18240\/ijo.2016.12.18","journal-title":"Int J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-020-04896-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:02:53Z","timestamp":1630461773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-020-04896-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04896-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. SEER data are anonymized and considered non-human subject research. Thus, it is IRB approval and HIPAA is exempted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}